

Cite this: *RSC Adv.*, 2018, 8, 10975

Received 7th February 2018

Accepted 14th March 2018

DOI: 10.1039/c8ra01185k

rsc.li/rsc-advances

A unimolecular theranostic system with H₂O₂-specific response and AIE-activity for doxorubicin releasing and real-time tracking in living cells†

Xiaoying Gao,^a Jie Cao,^a YINUO Song,^a Xiao Shu,^a Jianzhao Liu,^{*a} Jing Zhi Sun,^{ID a} Bin Liu,^{ID *b} and Ben Zhong Tang^{*acd}

A theranostic drug delivery system composed of tetraphenyl-ethene (AIEgen), benzyl boronic ester (trigger), and doxorubicin (drug) was designed and synthesized; its utilities for cell imaging, drug delivery tracking, and cancer cell cytotoxicity were evaluated.

Cancer is a disease that heavily threatens human lives and chemotherapy is known to be an effective route for cancer treatment.^{1,2} To achieve good therapeutic efficiency, controlled drug delivery systems are usually used in chemotherapy. Traditional drug delivery systems are nanocarriers that could specifically respond to a certain physiological environment (*e.g.*, redox, oxidation, pH, *etc.*), and release the drug at the same time.^{3–5} Recently, some theranostic drug delivery systems have been developed and attracted broad attention.^{6–9} Theranostic drug delivery systems that integrate diagnosis and therapy often respond to cancer-associated stimuli, release the drug, and simultaneously reveal an output signal change which can be tracked in a real time manner.^{6–9}

Fluorescent probing is one of the mostly used signaling techniques to display signal change upon drug release. Recently, fluorescent probes with AIE (aggregation-induced emission) property, namely AIEgens, have attracted great attention in both fundamental research and industrial applications.^{10–16} AIEgens are non-emissive when molecularly dissolved in solution but can be induced to emit strongly in aggregate state because of the restricted intramolecular motions (RIM).^{10–16} This unique RIM mechanism allows

AIEgens to emit efficiently at high concentrations and in solid state. Compared with conventional dyes with aggregation caused quenching (ACQ) property, AIEgens have shown higher photo-bleaching resistance and emission stability. In addition, they have shown lower cytotoxicity than inorganic quantum dots. Thus they are ideal candidates for cell imaging and drug delivery tracking.^{13–16}

The application of AIEgens to real-time imaging and tracking drug release process emerged as a novel strategy. For example, Liu *et al.* developed a light-up theranostic agent by tactfully linking a silole-based AIEgen, a cyclic RGD cancer cell-targeting peptide, a platinum Pt(IV) prodrug, and a stimulus responsive peptide together.¹⁷ The reductant of ascorbic acid in U87-MG cancer cells reduced the prodrug Pt(IV) to the active Pt(II) drug, which triggered apoptosis by activating the pro-apoptotic enzyme caspase-3. Subsequently, the enzyme cleaved the peptide to release the AIEgens, which aggregated in the cytoplasm and emitted strongly to report the drug-induced apoptosis. Using this strategy, another light-up theranostic agent containing a tetraphenylethene (TPE) AIEgen, a RGD peptide, a Pt(IV) prodrug and a stimulus-responsive peptide was designed, and it showed evident AIE-characteristics and expected cytotoxicity for breast cancer cells over normal cells. In a later design, both prodrugs of Pt(IV) and doxorubicin (DOX) were introduced into the light-up theranostic agent, which enhanced the apoptosis of cancer cells by the synergistic effect of the two drugs.¹⁸ In 2014, Zou, Liang and colleagues reported a fluorescence based self-indicating drug delivery system, which is capable of signaling spatiotemporal drug release with TPE and DOX composite nanoparticles (NPs).⁵ The emission of TPE molecules in the composite NPs was partially quenched by the DOX aggregates *via* a fluorescence resonance energy transfer (FRET) mechanism. After being taken up into lysosomes, the low internal pH triggered the detachment of DOX from the composite NPs and simultaneously enhanced the emission from AIEgens due to the absence of FRET process. This drug

^aMOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China. E-mail: liujz@zju.edu.cn

^bDepartment of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore, 117585, Singapore. E-mail: cheliub@nus.edu.sg

^cDepartment of Chemistry, Division of Biomedical Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China. E-mail: tangbenz@ust.hk

^dSCUT-HKUST Joint Research Laboratory, Guangdong Innovative Research Team, State Key Laboratory of Luminescent Materials and Devices, South China University of Technology, Guangzhou, 510640, China

† Electronic supplementary information (ESI) available: Experimental procedures, structure characterization data for the ABD system and particle size distribution of the ABD system in buffer solution. See DOI: 10.1039/c8ra01185k



delivery mode can track the sub-cellular location of the delivery system and the drug releasing site.

In this work, we developed a theranostic drug delivery system different from those reported in the literature. The system is constructed from an AIEgen (carboxylated TPE), a benzylboronic ester (BBE), and a DOX prodrug. It is abbreviated as ABD-system, and its working mechanism is illustrated in Scheme 1. In comparison with the previous work, a prime difference in our design lies on the BBE trigger, which is sensitive to hydrogen peroxide that is one of the cellular reactive oxygen species (ROS). ROS play key roles in controlling the function and health of cells, and alleviated ROS level has been correlated to cancerous cells.^{19–24} With their high reactivity, several drug delivery systems utilized ROS-sensitive functional groups, such as BBE and 2,4-dinitro-benzonyl, as triggers to activate prodrugs.^{25–28} So far, cellular ROS has never been used as the internal agent to trigger the drug release during which a fluorescence turn-on mechanism is utilized to monitor the progress in a real-time mode. When chemically bonded together *via* a self-immolative BBE linker,²⁹ the TPE and DOX units are close to each other. Moreover, the emission maximum (480 nm) of TPE is largely over-lapped with the absorption maximum (480 nm) of DOX. As DOX is weakly emissive due to its ACQ property, the ABD system is faintly emissive in solution or in aggregate state because of the unique emission mechanism of the AIEgen and the efficient FRET from TPE to DOX. If the ABD systems are internalized into a living cell with elevated cellular ROS level, the BBE linker would be cleaved, thereby the DOX and TPE units would be disassociated with each other and the FRET process is disrupted. As a result, DOX would be released and taken up into cell nucleus with red fluorescence. Meanwhile, the TPE molecules would form aggregate in the cellular plasma for their hydrophobic nature thereby the blue fluorescence could be detected. By monitoring the fluorescence changes in blue and red channels, the spatial and temporal information of the DOX release could be extracted.

The chemical structure of the theranostic ABD-system is shown in Scheme 1, and its synthetic route, preparation procedure, and characterization data of related intermediates are described in the Experiment section and ESI† (Fig. S1 to S12†). The spectral characterization results indicated that the expected ABD-system has been successfully obtained. With the



Scheme 1 Chemical structure of the theranostic drug delivery ABD-system and a schematic illustration of its working mechanism in a cell with elevated hydrogen peroxide level.

ABD-system in hand, we first investigated its fluorescence responses towards hydrogen peroxide H_2O_2 , in order to examine the proposed working mechanism shown in Scheme 1. The ABD-system itself in the solid state was weakly red emissive under the excitation of UV light due to efficient FRET, in spite of the strong emission of the TPE unit in solid state. In PBS buffer, almost no emission was recorded for the ABD-system upon excitation at 330 nm (Fig. 1), because the fluorescence of TPE is absorbed by DOX, while DOX is weakly fluorescent in aggregate state (the size distribution of the aggregates is shown in Fig. S13†). After the addition of H_2O_2 (100 μM) into buffer solution, blue fluorescence was observed and the brightness enhanced gradually with time. As shown in Fig. 1A and B, the emission peak appeared at around 480 nm, which was assigned to the emission from the aggregates of hydrophobic carboxylated TPE molecules, as indicated by its AIE property (Fig. S15 and S16†). This is because, when the BBE unit is oxidized by H_2O_2 , the linkage between TPE and DOX is broken, and DOX and carboxylated TPE are released (*cf.* Fig. S17†). The hydrophobic carboxylated TPE molecules form aggregates which emit blue fluorescence, while the DOX molecules are soluble in the buffer solution and emit weak red fluorescence. Since the distance between carboxylated TPE and DOX is far enough, FRET process is prohibited and hence the blue emission has been observed.




Fig. 1 (A) Changes in fluorescence (FL) spectra of the ABD-system (10 μM) in PBS buffer solution in the presence of H_2O_2 (100 μM) for different times (0 to 90 min). (B) Plot of FL intensity versus incubation time. The data are extracted from the spectra in (A). (C) FL spectra of the ABD-system in PBS buffer solution incubated with different concentrations of H_2O_2 for 90 min; (D) plot of the relative FL intensity versus H_2O_2 concentration. The data are extracted from (C), and the inset photographs show the FL images of the stock solutions with and without H_2O_2 . Concentration of the ABD-system (10 μM); PBS buffer solution (pH = 7.8, 10 mM, containing 1% DMSO); temperature: 37 $^{\circ}C$; excitation wavelength: 330 nm for FL measurement and 365 nm for photograph.



As indicated by the experimental data shown in Fig. 1A and B, the emission intensity increased gradually and the spectral features reached a steady state (unchanged) after 80 min. The experimental results shown in Fig. 1C and D were obtained by reacting with H_2O_2 for 90 min. A prominent dose-dependent behavior is observed. The emission intensity continuously increases with the increasing H_2O_2 concentration from 10 to 90 μM , and the photograph clearly displays the blue emission from the AIEgen (inset of Fig. 1D). A fluorescence intensity enhancement of 142-fold was observed when the H_2O_2 concentration was increased to 90 μM .

Considering that other ROS, RNS (reactive nitrogen species) and RSS (reactive sulphur species), such as O_2^- , GSH, ClO^- , $\cdot\text{OH}$, $^1\text{O}_2$, *tert*-butyl hydroperoxide (TBHP), alkylperoxyl radical ($\text{ROO}\cdot$), NO_2^- , NO_3^- , and S_2^- , may coexist with H_2O_2 in physiological environment, we also examined the fluorescent response of the ABD-system to the interfering species. As shown in Fig. 2, except for H_2O_2 , all of the other reactive species can only lead to very small changes in fluorescence intensity under the identical experimental condition. Such an excellent selectivity is ascribed to the rational molecular design, since among the ROS we tested, only H_2O_2 can react with the BBE unit to induce the separation between TPE and DOX units and then turn on fluorescence emission.

Based on the above results, the ABD system works well in buffer solutions. The blue emission from the aggregate of carboxylated TPE can be specifically triggered by H_2O_2 , indicating the releasing of DOX. To check whether this system can work well in living cells, we incubated HeLa cells in different conditions and monitored the fluorescence from the cells using confocal laser scanning microscopy (CLSM) technique. When HeLa cells were loaded with 10 μM ABD-system and incubated at 37 $^\circ\text{C}$ for 2 h, no fluorescence emission could be recorded in blue channel (420–540 nm), but red emission with moderate

intensity was recorded in the spectral window of 550–650 nm. The overlay (Fig. 3D) of the bright field (Fig. 3C) with the fluorescent images suggest that the ABD-system is uniformly distributed in the cytoplasm.

When ABD-system loaded HeLa cells were treated with 5 $\mu\text{g mL}^{-1}$ phorbol-12-myristate-13-acetate (PMA) for 30 min and then incubated for another 2.5 hours, evident blue emission was detected in spectral window of 420–540 nm (Fig. 3E). Meanwhile, red emission was also collected in the wavelength range of 550–650 nm (Fig. 3F). Since PMA is an agent widely used to *in situ* induce the generation of H_2O_2 in living cells, the introduction of PMA can effectively elevate the H_2O_2 level and thereby trigger the release of both carboxylated TPE and DOX in the cytoplasm. The generated carboxylated TPE molecules were insoluble in aqueous medium (*e.g.*, cytoplasm), and hence formed aggregates. Due to the inhibited FRET process induced by DOX leaving and the TPE aggregate formation, strong blue fluorescence from TPE donor was recorded according to the RIM mechanism. At the same time, DOX molecules were also released into cytoplasm. The merged image indicates that the blue and red emissions from the aggregates of the carboxylated TPEs and DOXs have good overlap and are distributed all over the cytoplasm.

After further incubation for additional 3 h, the blue emission still existed in the cytoplasm (Fig. 3I), while the red emission could be observed in the cell nucleus (Fig. 3J). This indicates that some DOX molecules are translocated into cell nucleus. This observation is reasonable because DOX is a drug that works on DNA. In the overlay image (Fig. 3L), the entities with purple fluorescence are assigned to cell nucleus, indicative of the colour mixing of blue and red emissions. The surrounding



Fig. 2 FL response of the ABD system (10 μM) to a series of ROS (100 μM) in PBS buffer solution. I_0 and I are the FL intensity of the ABD-system in PBS buffer solution in the presence of ROS, RNS, and RSS including H_2O_2 , O_2^- , GSH, ClO^- , $\cdot\text{OH}$, $^1\text{O}_2$, TBHP, $\text{ROO}\cdot$, S_2^- , NO_2^- and NO_3^- . PBS buffer solution (pH = 7.8, 10 mM, containing 1% DMSO); temperature: 37 $^\circ\text{C}$; excitation wavelength: 330 nm; reaction time: 100 min.




Fig. 3 Confocal images of HeLa cells after incubation with TPE–DOX with different treatment; (A–D) no more treatment; (E–H) cells treated with PMA for 30 min and incubated for another 2.5 hour; (I–L) cell treated with PMA for 30 min and incubated for another 5.5 hour. Blue channel: excitation wavelength: 405 nm; collection wavelength: 420–540; red channel: excitation wavelength: 488 nm; collection wavelength: 550–650 nm. All images share the same scale bar (20 nm).



blue fluorescence comes from the aggregated carboxylated TPEs.

In order to evaluate therapeutic performance of the ABD system, cell viability was studied using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. As shown in Fig. 4, without the ABD system, the cell viability is as high as 98% in the presence of PMA under standard incubation condition. PMA itself has no therapeutic effect on HeLa cells. Without the treatment of PMA, the presence of ABD system could not induce the therapeutic effect, and the cell viabilities in different concentrations and incubation time were almost the same, as suggested by the data in Fig. 4. In sharp contrast, when activated with PMA, cell viabilities decreased dramatically and synergistically with the increment of prodrug concentration and incubation time. As a direct evidence, the bright field images (Fig. 3C, G and K) and the confocal fluorescent images demonstrate that the morphologies of HeLa cells changed significantly upon treated with ABD and PMA for hours. These results strongly prove that ABD system has good therapeutic effects on HeLa cells.

In summary, an ABD-system consisting of carboxylated TPE (AIEgen), active linker (benzyl-boronic ester) and DOX (drug) moieties has been designed, synthesized and characterized. Its drug releasing and fluorescent tracking processes and its therapeutic effect have been studied. In living HeLa cells incubated with the ABD-system, sole red emission can be observed. After treatment with PMA, H_2O_2 is generated *in situ* and it reacts with the benzyl-boronic ester moiety, leading to the decomposition of the ABD system and the spatial separation of carboxylated TPE and DOX moieties. As a result, both of the blue emission from the AIEgen and red emission from DOX molecules have been monitored in the respective spectral channels, due to restricted FRET between AIEgens and DOX. Based on the dual emission colors, the DOX releasing can be monitored. After a short period of time, the released DOX molecules enter into nucleus to realize its therapeutic function, which is revealed by the observation of the red emission in the nucleus region. The therapeutic effect has been estimated by the MTT experiments.




Fig. 4 Dose-dependent cytotoxicity of ABD system to HeLa cells with and without PMA treatments, which were estimated by using standard MTT assay.

In addition, the ABD system shows high stability in the pH range from 4 to 9 and good selectivity over other interfering reactive species including OCl^- , O_2^- , $\cdot OH$, GSH, 1O_2 , TBHP, $ROO\cdot$, NO_2^- , NO_3^- and S_2^- , which are also involved in biological systems.

Conclusions

In short, the ABD system demonstrates multiple functions of fluorescent cell imaging, drug releasing and drug delivery process tracking, and thus it is a novel and promising candidate for theranostic drug delivery system.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was financially supported by the National Science Foundation of China (51573158, 21788102), the key project of Ministry of Science and Technology of China (2013CB834704), the Innovation and Technology Commission (ITC-CNERC-14SC01), and the Research Grants Council of Hong Kong (16301614, 16305015, 16308016, N_HKUST604/14 and A-HKUST605/16). J. L. thanks the Thousand Young Talents Plan of China and Hundred Talents Program of Zhejiang University. B. Z. T. is also grateful for the support from the Science and Technology Plan of Shenzhen (JCYJ201602229205601482), B. L. thanks the National University of Singapore (R279-000-482-133) for financial support.

Notes and references

- H. A. Idikio, *J. Cancer*, 2011, **2**, 107.
- J. W. Kim and C. V. Dang, *Cancer Res.*, 2006, **66**, 8927.
- D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit and R. Langer, *Nat. Nanotechnol.*, 2007, **2**, 751.
- M. E. Calderera-Moore, W. B. Liechty and N. A. Peppas, *Acc. Chem. Res.*, 2011, **44**, 1061.
- X. D. Xue, Y. Y. Zhao, L. R. Dai, X. Zhang, X. H. Hao, C. Q. Zhang, S. D. Hao, J. Liu, C. Liu, A. Kumar, W. Q. Chen, G. Z. Zou and X. J. Liang, *Adv. Mater.*, 2014, **26**, 712.
- R. Kumar, W. S. Shin, K. Sunwoo, W. Y. Kim, S. Koo, S. Bhuniya and J. S. Kim, *Chem. Soc. Rev.*, 2015, **44**, 6670.
- X. Wu, X. Sun, Z. Guo, J. Tang, Y. Shen, T. D. James, H. Tian and W. Zhu, *J. Am. Chem. Soc.*, 2014, **136**, 3579.
- Y. Yuan, R. T. K. Kwok, R. Zhang, B. J. Tang and B. Liu, *Chem. Commun.*, 2014, **50**, 11465.
- M. H. Lee, J. Y. Kim, J. H. Han, S. Bhuniya, J. L. Sessler, C. Kang and J. S. Kim, *J. Am. Chem. Soc.*, 2012, **134**, 12668.
- Y. Hong, J. W. Y. Lam and B. Z. Tang, *Chem. Soc. Rev.*, 2011, **40**, 5361.
- J. Mei, N. L. C. Leung, R. T. K. Kwok, J. W. Y. Lam and B. Z. Tang, *Chem. Rev.*, 2015, **115**, 11718.



- 12 J. Mei, Y. Hong, J. W. Y. Lam, A. J. Qin, Y. Tang and B. Z. Tang, *Adv. Mater.*, 2014, **26**, 5429.
- 13 M. Gao and B. Z. Tang, *Drug Discovery Today*, 2017, **22**, 1288.
- 14 X. G. Gu, R. T. K. Kwok, J. W. Y. Lam and B. Z. Tang, *Biomaterials*, 2017, **146**, 115.
- 15 F. Hu and B. Liu, *Org. Biomol. Chem.*, 2016, **14**, 9931.
- 16 D. Ding, K. Li, B. Liu and B. Z. Tang, *Acc. Chem. Res.*, 2013, **46**, 2441.
- 17 Y. Yuan, R. T. K. Kwok, B. J. Tang and B. Liu, *J. Am. Chem. Soc.*, 2014, **136**, 2546.
- 18 Y. Yuan, R. T. K. Kwok, R. Zhang, B. J. Tang and B. Liu, *Chem. Commun.*, 2014, **50**, 11465.
- 19 T. Finkel and N. J. Holbrook, *Nature*, 2000, **408**, 239.
- 20 B. C. Dickinson and C. J. Chang, *Nat. Chem. Biol.*, 2011, **7**, 504.
- 21 J. M. McCord, *N. Engl. J. Med.*, 1985, **312**, 159.
- 22 P. J. Murray and T. A. Wynn, *Nat. Rev. Immunol.*, 2011, **11**, 723–737.
- 23 A. Mantovani, P. Allavena, A. Sica and F. Balkwill, *Nature*, 2008, **454**, 436.
- 24 X. Y. Gao, G. X. Feng, P. N. Manghnani, F. Hu, N. Jiang, J. Z. Liu, B. Liu, J. Z. Sun and B. Z. Tang, *Chem. Commun.*, 2017, **53**, 1653.
- 25 Z. Q. Wang, H. Wu, P. L. Liu, F. Zeng and S. Z. Wu, *Biomaterials*, 2017, **139**, 139.
- 26 X. Liu, J. J. Xiang, D. C. Zhu, L. M. Jiang, Z. X. Zhou, J. B. Tang, X. R. Liu, Y. Z. Huang and Y. Q. Shen, *Adv. Mater.*, 2016, **28**, 1743.
- 27 R. Kumar, J. Han, H. J. Lim, W. X. Ren, J. Y. Lim, J. H. Kim and J. S. Kim, *J. Am. Chem. Soc.*, 2014, **136**, 17836.
- 28 E. J. Kim, S. Bhuniya, H. Lee, H. M. Kim, C. Cheong, S. Maiti, K. S. Hong and J. S. Kim, *J. Am. Chem. Soc.*, 2014, **136**, 13888.
- 29 M. E. Roth, O. Green, S. Gnaim and D. Shabat, *Chem. Rev.*, 2016, **116**, 1309.

